Search

Články časopisu Proteomic profiling of the thrombin-activated canine platelet secretome (CAPS)

Author of the article: Signe E. Cremer, James L. Catalfamo, Robert Goggs, Stefan E. Seemann, Annemarie T. Kristensen, Marjory B. Brooks Source: PLOS One | 11/2019 1. 11. 2019

News Seventy-day Shedding of SARS-CoV-2 in an Immunocompromised Patient with CLL –⁠ A Case Study

A team of American and British experts published the case of a 71-year-old woman with chronic lymphocytic leukemia (CLL) and hypogammaglobulinemia who tested positive for SARS-CoV-2. Despite an asymptomatic course of infection, virus shedding was documented for up to 10 weeks, and viral RNA presence was detected for 15 weeks after the initial detection. The longest recorded virus shedding at the time of the article's publication was 20 days after the first positive test result.

Source: Chronic Lymphocytic Leukemia 26. 2. 2021

News San Antonio: Results of Breast Cancer Treatment with Combination of Pertuzumab, Trastuzumab, and AI After 6 Years

The virtual conference dedicated to breast cancer, which took place December 8–11 in San Antonio, USA (San Antonio Breast Cancer Symposium; SABCS 2020), presented, among other things, the results of the final analysis of the multicenter randomized open-label PERTAIN study.

Source: Breast Carcinoma 11. 1. 2021

News Turoctocog Alfa Pegol and Its Impact on Health-Related Quality of Life

The presented work is based on the results of studies that evaluated how the administration of turoctocog alfa pegol affects the quality of life in individuals with severe hemophilia A. The obtained data also reflect the level of patient satisfaction with this treatment.

Source: Hemophilia with Movement 25. 2. 2021

News Do antiglaucoma drugs induce inflammation and irritation on the eye surface? Results of a 2-year randomized study

Eye drops for glaucoma treatment may contain preservatives responsible for eye irritation and possibly chronic inflammation. The study presented below is the first to compare the profile of inflammatory cytokines and eye irritation in patients using topical antiglaucoma drugs with and without preservatives.

Source: Treatment of Glaucoma 18. 2. 2021

News How Will the New Player in Dyslipidemia Therapy Change the "Rules of the Game"?

Inclisiran, as an innovative drug indicated for adult patients with primary hypercholesterolemia or mixed dyslipidemia, was registered in the European Union at the end of 2020. Internists and cardiologists can now share their first experiences with this therapy in real practice. Case reports from the Czech Republic have also been published in specialized literature.

Source: Chronic Heart Failure and Lipidology 12. 12. 2022

News Pharmacokinetic Comparison of Two EHL Products in Hemophilia A

According to a Canadian study published last year, certain pharmacokinetic differences were observed between two extended half-life factors.

Source: Hemophilia 8. 2. 2022

News Monitoring of Joint Health is an Important Part of Hemophilia Care

Joint health has become a key aspect of the quality of life for people with hemophilia. The possibilities of monitoring early joint damage in hemophiliacs were evaluated in a recently published British study.

Source: Hemophilia 18. 8. 2021

News Rurioctocog alfa pegol in previously treated patients with severe hemophilia A: What findings did the long-term continuation study bring?

Rurioctocog alfa pegol (Adynovi) is a recombinant coagulation factor VIII modified by pegylation, which results in an approximately 1.5× prolonged biological half-life compared to standard half-life FVIII. Previous studies have already confirmed the favorable profile of this drug in prophylaxis for patients with hemophilia A. Recently published results of a prospective multicenter continuation study in children and adult patients under 75 years old with severe hemophilia A (baseline FVIII level < 1%) were based on an observation period averaging 2.2 years.

Source: Hemophilia 2. 11. 2020

News Issues of Adherence to Thromboprophylaxis with Enoxaparin in Patients with Sickle Cell Disease

Thromboembolic disease is one of the common complications in patients with sickle cell disease (SCD). However, a recently published study shows that patient adherence to prescribed thromboprophylaxis is not very high.

Source: Thromboprophylaxis 3. 1. 2024

News ASH 2020: Efficacy and Safety of Emicizumab in Long-term Follow-up

At the virtual meeting of the American Society of Hematology (ASH) in December 2020, the latest data concerning the long-term follow-up of participants in the HAVEN 1−4 clinical trials with emicizumab were published.

Source: Quality Life Even with Hemophilia 4. 1. 2021

News What does the analysis of the CHESS PAEDs study say about the relationship between physical activity and the frequency of bleeding events in children with hemophilia A?

Currently, there is limited published data addressing the relationship between physical activity and the occurrence of bleeding events in children with hemophilia A. To gain insights into this topic in real-world practice, data from the CHESS PAEDs study were analyzed. The results were presented in the poster section of the virtual congress of the International Society on Thrombosis and Haemostasis (ISTH).

Source: Quality Life Even with Hemophilia 27. 11. 2021

News ASH 2020: Two Real-World Perspectives on Experiences with Emicizumab Prophylaxis

Data presented at the ASH 2020 congress bring interesting insights regarding the administration of emicizumab in real clinical practice. It provides comprehensive information on the relatively high number of individuals treated with emicizumab in relation to persistence on treatment and adherence to it. Data from the EUHASS registry confirms the good safety profile of this treatment even in regular clinical practice across Europe.

Source: Quality Life Even with Hemophilia 4. 1. 2021

News ESC 2022: What Do the Latest Real-World Data Say About the Use of DOACs in Atrial Fibrillation?

Why are real-world data so important? What new insights can they provide about established medications, such as direct oral anticoagulants (DOACs), in the treatment of patients with atrial fibrillation (AF)? What makes the GLORIA-AF registry unique, and what insights have been published from it this year? These topics were also discussed at the ESC 2022 Congress.

Source: Anticoagulant Treatment 6. 10. 2022

News European Registry of Patients with Alpha-1 Antitrypsin Deficiency EARCO Enrolls Patients

Insufficient identification of patients with alpha-1 antitrypsin deficiency (AATD) and a lack of knowledge about this disease have led to the launch of the European Registry EARCO, which is currently enrolling patients. The aim is to better describe the pathophysiology of the disease and the prognosis of these patients, and to create a validated prognostic tool to aid clinical decision-making.

Source: Deficiency of Alpha-1-Antitrypsin 12. 4. 2021